1. Latest News
  2. Submit Press Release

Pharmacovigilance Brings Drug Safety Beyond Compliance

IQPC’s Pharmacovigilance North America Summit brings together industry experts to address top industry concerns

July 8, 2011 - PRLog -- PHILADELPHIA, PA  – Pharma IQ, a division of IQPC, announces the Pharmacovigilance North America Conference, to be held September 26 to 28, 2011 in Philadelphia.  The Conference brings together pharmaceutical companies and professionals working in drug/patient safety, quality assurance, risk management, compliance, regulatory and government affairs, providing a networking forum to benchmark against developing and proven strategies.

Regulators in the pharmaceutical industry are now demanding increasingly proactive surveillance programs that include comprehensive risk management plans and pharmacovigilance signal detection and analysis throughout a product's lifecycle.

In addition to meeting these new regulation requirements, pharmaceutical companies are faced with the task of regaining the trust of patients, healthcare providers and regulators.  Recent drug withdrawals have led to calls for pharmaceutical companies to show a demonstrated commitment to safety that goes beyond mere compliance. In May, U.S. regulators restricted use of London-based GlaxoSmithKline Plc (GSK)’s Avandia, after a study showed a 43 percent increased risk of heart attacks among patients taking the medicine. The drug was ordered pulled from pharmacy shelves and subsequently was available only through a special program. Sales of Avandia fell to $680 million last year from $1.8 billion in 2007.

Pharmacovigilance North America is designed to help companies take the lead in creating a proactive and long-term approach to drug management and safety. Over twenty-one in-depth case studies and workshops set out best practices and innovative solutions addressing top industry concerns including:

• Addressing the Importance of Developing & Implementing a Pre-Marketing Plan
• FDA Developments and Future Direction
• Designing Post-Approval Safety Studies
• Best Practices and Methodology of Post-Approval Non-Interventional Studies
• Utilizing a Fully Outsourced Model for Case Processing
• Pharmacovigilance Compliance in a Global Environment
• Difficulties with Investigating Reporting
• Methodological Advances in Post-Approval Studies
• Life-Cycle Management of the Product Safety Profile
• The Future of Drug Safety
• Unintended Consequences on Spontaneous Reporting

Case studies and best practices will be shared from leading industry experts including RTI Health Solutions, Novartis Pharmaceuticals, Genzyme Corporation, Bayer Healthcare LLC, Pfizer Inc., Cephalon and more.

For more information on the IQPC Pharmacovigilance North America Conference, please visit the Pharmacovigilance North America Conference website at http://tinyurl.com/5vp5fxw or contact Claudia Rubino, Program Director at Claudia.Rubino@iqpc.com.

# # #

About IQPC
IQPC (www.iqpc.com) provides business executives with tailored practical conferences, large-scale events, topical seminars and in-house training programs. Producing over 1,500 events annually around the world, IQPC continues to grow and has offices in cities across six continents including: Berlin, Dubai, London, New York, Sao Paulo, Singapore, Sydney, and Toronto.


--- End ---

Click to Share

Contact Email:
***@iqpc.com Email Verified
Source:Ashley Rowe
Phone:1 800 882 8684
Location:New York City - New York - United States
Tags:Pharmacovigilance, Pharma, Drug Safety, Drug Development, Pharmaceuticals, Drug Compliance, Quality Assurance
Last Updated:Jul 08, 2011
Verified Account Email Address
Verified Account Phone Number

Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “


Like PRLog?
Click to Share